NCT05315687View on ClinicalTrials.gov

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 17, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Carcinoma in the LiverPrognostic Stage IV Breast Cancer AJCC v8
Interventions
DEVICE

Y-90 SIR-Spheres

Y-90 SIR-Spheres

PROCEDURE

Yttrium-90 Microsphere Radioembolization

Undergo Y90 radioembolization

OTHER

Systemic Therapy

Systemic Therapy

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Sirtex Medical
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Sirtex Medical

INDUSTRY

lead

Emory University

OTHER

NCT05315687 - Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | Biotech Hunter | Biotech Hunter